A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma

BACKGROUND: Targeting PLK1 has recently been proven as a viable therapeutic strategy against oesophageal squamous cell carcinom (ESCC). Therefore, this study aimed to explore whether the PLK1 inhibitor BI2536 is able to sensitize ESCC cells to cisplatin (DDP) and determine the underlying mechanisms....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:EBioMedicine
Hlavní autoři: Wu, Mengjiao, Wang, Yan, Yang, Di, Gong, Ying, Rao, Feng, Liu, Rui, Danna, Yeerken, Li, Jinting, Fan, Jiawen, Chen, Jie, Zhang, Weimin, Zhan, Qimin
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2019
Témata:
Research paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442225/
https://ncbi.nlm.nih.gov/pubmed/30876762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.02.012
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky